Results 81 to 90 of about 912 (125)
Obesity Reviews, Volume 27, Issue 8, August 2026.ABSTRACT Introduction Weight loss results in reduced energy expenditure (EE) due to body composition alterations (e.g., fat‐free mass and fat mass losses) and mass‐independent adaptations in EE (e.g., hormones). Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are indicated for obesity management; however, their effects on EE remain unclear ...
Flavio T. Vieira +8 more
wiley +1 more source
Hypoglycemia associated with off-label sitagliptin use
International Medical Case Reports Journal, 2008 Heather P Whitley1,2, Kristi Kelley11Department of Pharmacy Practice, Auburn University Harrison School of Pharmacy, Auburn, AL, USA; 2Department of Community and Rural Medicine, University of Alabama School of Medicine, Tuscaloosa, AL, USAPurpose: To ...
Heather P Whitley, Kristi Kelley
doaj
Chronicle of Diabetes Research and PracticeIntroduction: The present study evaluated the bioequivalence of a fixed-dose combination (FDC) of sitagliptin and glimepiride with the originator reference product.
Prashant Kumthekar +4 more
doaj +1 more source
Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
Diabetes, Metabolic Syndrome and Obesity, 2009 Jonathan K ReynoldsWashington State University, College of Pharmacy, Pullman, WA, USAAbstract: JanumetTM, a fixed dose combination of sitagliptin/metformin HCL manufactured by Merck Pharmaceuticals, has received US Food and Drug Administration approval ...
Jonathan K Reynolds
doaj
پزشکی بالینی ابن سینا, 2018 Background and Objective: Diabetes mellitus is one of the most commonly reported diseases that is associated with insulin resistance and increased blood glucose levels.
Elham Mahabadi-Ashtiyani +4 more
doaj
Patient Preference and Adherence, 2015 Qiang Du, Yan-Jun Wang, Sheng Yang, Ping HanDepartment of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People’s Republic of ChinaAbstract: The prevalence of diabetes mellitus (DM) continues to increase each ...
Du Q, Wang YJ, Yang S, Han P
doaj
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Expert Opinion on Pharmacotherapy, 2011
The ever-increasing burden of type 2 diabetes mellitus (T2DM) and inadequate control in the majority of patients has led to a quest for newer therapeutic options. There have been recent exciting advances in the treatment of T2DM, targeting the enteroinsular axis with incretin-based therapies that include the dipeptidyl peptidase IV (DPP-IV) inhibitors ...
Sreevidya, Subbarayan, Mark, Kipnes
exaly +3 more sources
The ever-increasing burden of type 2 diabetes mellitus (T2DM) and inadequate control in the majority of patients has led to a quest for newer therapeutic options. There have been recent exciting advances in the treatment of T2DM, targeting the enteroinsular axis with incretin-based therapies that include the dipeptidyl peptidase IV (DPP-IV) inhibitors ...
Sreevidya, Subbarayan, Mark, Kipnes
exaly +3 more sources
Drugs, 2007
Sitagliptin, an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. This increases active incretin and insulin levels, and decreases glucagon levels and post-glucose-load glucose excursion.
Daniel Drucker +2 more
openaire +3 more sources
Sitagliptin, an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. This increases active incretin and insulin levels, and decreases glucagon levels and post-glucose-load glucose excursion.
Daniel Drucker +2 more
openaire +3 more sources